Abstract

To the editor: Hutchinson and associates (1) report a salt wasting nephropathy in 10% of patients with lung cancer treated with cisplatinum. We saw a similar occurrence in 1 of 25 patients on a phase-I trial using carboplatinum in refractory patients who had relapses with acute leukemia (2).